Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH -7.58% EV-to-EBITDA is -24.26 as of Jul. 16, 2026. The stock has 4 warning signs investors should review. Among 739 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks worse than 135317.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CTT Pharmaceutical Holdings's enterprise value is $3.59 Mil.
CTT Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.15 Mil. Therefore, CTT Pharmaceutical Holdings's EV-to-EBITDA for today is -24.26.
The historical rank and industry rank for CTT Pharmaceutical Holdings's EV-to-EBITDA or its related term are showing as below:
CTTH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.24 Med: 0 Max: 0
Current: -24.26
CTTH's EV-to-EBITDA is ranked worse than 100% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.13
vs CTTH: -24.26
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CTT Pharmaceutical Holdings's PE Ratio (TTM) for today is calculated as:
CTT Pharmaceutical Holdings's share price for today is $0.061.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CTT Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTT Pharmaceutical Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CTT Pharmaceutical Holdings's EV-to-EBITDA falls into.
CTT Pharmaceutical Holdings's current Enterprise Value is $3.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CTT Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTT Pharmaceutical Holdings (CTTH) has a EV-to-EBITDA of -24.26 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CTT Pharmaceutical Holdings. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #999999 out of 739 companies in the Drug Manufacturers industry.
Is CTT Pharmaceutical Holdings' EV-to-EBITDA too high?
CTT Pharmaceutical Holdings' current EV-to-EBITDA is -24.26. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #999999 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CTT Pharmaceutical Holdings' EV-to-EBITDA compare to BUDZ and SBFM?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #999999 out of 739 companies for EV-to-EBITDA. This places CTT Pharmaceutical Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.13, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CTT Pharmaceutical Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current EV-to-EBITDA is -24.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current EV-to-EBITDA of -24.26. The current EV-to-EBITDA is -24.26. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current EV-to-EBITDA is -24.26 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
